Clinical subsets, skin thickness progres
β
Achini Perera; Noreen Fertig; Mary Lucas; Tatiana S. Rodriguez-Reyna; Paul Hu; V
π
Article
π
2007
π
John Wiley and Sons
π
English
β 129 KB
π 2 views
## Abstract ## Objective To describe the clinical and laboratory features and natural history of the disease in systemic sclerosis (SSc; scleroderma) patients with antiβtopoisomerase I (antiβtopo I) antibody who have different skin thickness progression rates (STPRs). ## Methods SSc patients (n